WO2004002486A2 - Ciprofloxacin hci - Google Patents
Ciprofloxacin hci Download PDFInfo
- Publication number
- WO2004002486A2 WO2004002486A2 PCT/PH2003/000006 PH0300006W WO2004002486A2 WO 2004002486 A2 WO2004002486 A2 WO 2004002486A2 PH 0300006 W PH0300006 W PH 0300006W WO 2004002486 A2 WO2004002486 A2 WO 2004002486A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amount
- pharmaceutical composition
- starch
- ciprofloxacin hydrochloride
- conform
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to Ciprofloxacin Hydrochloride-containing compositions, useful for the treatment of diseases.
- the main composition is Ciprofloxacin Hydrochloride and the chemical name in accordance with the Merck Index II th Edition, page 360 (1989) has the
- Ciprofloxacin is a broad-spectrum antibacterial active principle.
- Ciprofloxacin Hydrochloride may easily be obtained on the market place or may be prepared by any of the methods disclosed in Spanish Patents Es- 2006099 and ES-2006098.
- Ciprofloxacin Hydrochloride is a white or off-white powder, which is odorless and has a bitter taste with a wide range antibacterial activity against Excherichia Coli, Klebsiella SPP., and other Enterobacter SPP., Bacillus - negative.
- the antibacterial action against Pseudomonas aerugenosa, golden yellow Staphylococcus and Streptococcus pneumoniae is better than other known derivatives i.e. Norfloxacin and Peifloxacin but the antibacterial action against Streptococcus SPP. Is less than Penicillin kinds of antibiotic.
- Ciprofloxacin Hydrochloride may be used in combination with an amino glycoside or with beta-lactam antibiotics.
- the present inventor is aware of the existence of prior art describing ciprofloxacin pharmaceutical preparations which may be used for combating diseases whereby, in view of the high efficacy and broad spectrum of this antibacterial active principle, there is a felt the desirability of developing new compositions containing it, suitable for such application.
- the invention seeks to provide aqueous ciprofloxacin compositions suitable for use in the treatment of the following infections caused by sensitive bacteria: 1. Upper respiratory tract infections including tonsillitis, sinusitis, otitis media and pharynx inflammation.
- Lower respiratory tract infections including acute and clironic bronchitis, bronchiectasis and pneumonia.
- Urinary tract infections including urethritis, cystitis, pyelonephritis, prostatitis and pelvic inflammatory.
- Gastro-intestinal infections including enteric fever and infective diarrhea.
- composition according to the present invention characterized in that they comprise the following essential components, in the amounts given hereinafter. i. 300 g of Ciprofloxacin; ii. 65 g of starch; iii. 18 g of Carboxymethyl starch Sodium; iv. 4 g of Magnesium Stearate
- the daily dose of the composition of the present invention can vary over broad limits depending on several factors, e.g. on the activity of the active ingredients, the patient's condition and age, the severity of the disease.
- the oral dose as a rule usual dose; single dose is 200-250mg; severe symptom; single dose is 400-500mg, twice a day taken with boiled water. It has to be stressed that these doses figures are intended for information only, and administered dose must be determined each time by the physician therapeutist.
- Starch and Carboxymethyl starch into a container ii. Adding some amount of starch thick liquid and stir until a soft material formed in the previous step and then dry it at a temperature preferably 70 C for 4 hours; iii. Granulating the soft material formed in the previous step and then dry it at a temperature preferably 70 C for 4 hours; iv. Take it out and arrange the grain; v. Adding some amount of Magnesium Stearate in order to fill well in a capsule using an automatic filling machine;
- the capsules are packaged in a blister foil. It does obtained compositions, which have excellent properties with regard to physical and microbial stability, without the need to use preservatives and are particularly appropriate for oral administration.
- the retention time of sample A corresponds to that of the standard.
- A The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that of the standard preparation obtained as directed in the Assay.
- Tolerances An amount of C 1 H 18 FN 3 O 3 . HCI equivalent to not less than 80% (Q) of the labeled amount of Ciprofloxacin C 1 H 18 FN 3 O 3 is dissolved in 30 minutes.
- Assay preparation Transfer 5 capsules to a 500-mL volumetric flask, add about 400 mL of water, and sonicate for about 20 minutes. Dilute with water to volume, and mix. Dilute an accurately measured volume of this solution quantitatively with water to obtain containing the equivalent of about 0.25 mg of Ciprofloxacin per mL.
- Procedure - proceed as directed for Procedure in the Assay under Ciprofloxacin Hydrochloride. Calculate the quantity in mg of Ciprofloxacin (C 17 H 18 FN 3 O 3 ) in each capsule taken by the formula:
- Ciprofloxacin and anhydrous Ciprofloxacin Hydrochloride are the molecular weights of Ciprofloxacin and anhydrous Ciprofloxacin Hydrochloride, respectively
- C is the concentration, in mg per mL, of USP Ciprofloxacin Hydrochloride RS in the Standard preparation, calculated on the anhydrous basis.
- L is the labeled quantity, in mg per mL of Ciprofloxacin in the Assay preparation, based on the labeled quantity per capsule and the extend of dilution
- rL and rs are the ciprofloxacin peak responses obtained from the Assay preparation and the Standard preparation, respectively.
- Ciprofloxacin Hydrochloride capsules Three batches (980 01, 980 02, 980 03) of Ciprofloxacin Hydrochloride capsules have been subjected to stability tests under 20°C ⁇ 2°C and 0% RH ⁇ 5%. So far, two year' stability results are available.
- the container to be used is the same as the actual packaging used for storage and distribution.
- Item 3.1 was tested by estimation, items 3.2, 3.3, 3.4 were tested in accordance with section 7 "Test procedure for finished products".
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003261038A AU2003261038A1 (en) | 2002-06-27 | 2003-06-18 | Ciprofloxacin hci |
EP03761874A EP1539167A2 (en) | 2002-06-27 | 2003-06-18 | Ciprofloxacin hci |
US10/519,467 US20050232985A1 (en) | 2002-06-27 | 2004-12-27 | Ciprofloxacin hcl |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PH12002000485 | 2002-06-27 | ||
PH1-2002-000485 | 2002-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004002486A2 true WO2004002486A2 (en) | 2004-01-08 |
WO2004002486A3 WO2004002486A3 (en) | 2004-04-08 |
Family
ID=29997606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PH2003/000006 WO2004002486A2 (en) | 2002-06-27 | 2003-06-18 | Ciprofloxacin hci |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050232985A1 (en) |
EP (1) | EP1539167A2 (en) |
CN (1) | CN1678319A (en) |
AU (1) | AU2003261038A1 (en) |
WO (1) | WO2004002486A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113075147B (en) * | 2021-02-26 | 2022-09-27 | 南开大学滨海学院 | Sasa class magnesium metal organic complex material, preparation method thereof and application of material in detecting sulfur-containing malodorous substances |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2260345T3 (en) * | 2001-03-07 | 2006-11-01 | Dainippon Sumitomo Pharma Co., Ltd. | METHOD FOR MANUFACTURING PHARMACO GRANULES, PHARMACEUTICAL AND PHARMACEUTICAL PREPARATION GRANULES CONTAINING PHARMACO GRANULES. |
-
2003
- 2003-06-18 WO PCT/PH2003/000006 patent/WO2004002486A2/en not_active Application Discontinuation
- 2003-06-18 AU AU2003261038A patent/AU2003261038A1/en not_active Abandoned
- 2003-06-18 CN CNA038202077A patent/CN1678319A/en active Pending
- 2003-06-18 EP EP03761874A patent/EP1539167A2/en not_active Withdrawn
-
2004
- 2004-12-27 US US10/519,467 patent/US20050232985A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [Online] WANG ET AL.: 'Ciflodal film-coated tablets', XP002971669 Retrieved from STN Database accession no. 2002:624450 & CHINA CHEMICAL & PHARMACOLOGICAL CO., LTD. 01 September 2000, TAIWAN, * |
GENNARO ET AL., 1990, REMINGTON'S PHARMACEUTICAL SCIENCES article 'Oral solid dosage forms', pages 1641 - 1647, XP002971670 18th Edition * |
PARFITT K.: 'Martindale: The Complete Drug Reference', 1999 pages 185 - 189, XP002971671 32nd Edition * |
Also Published As
Publication number | Publication date |
---|---|
CN1678319A (en) | 2005-10-05 |
US20050232985A1 (en) | 2005-10-20 |
EP1539167A2 (en) | 2005-06-15 |
AU2003261038A1 (en) | 2004-01-19 |
WO2004002486A3 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Puttewar et al. | Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin | |
CN111050764A (en) | β -hydroxybutyrate and butanediol S enantiomers and methods of use thereof | |
US5605889A (en) | Method of administering azithromycin | |
ES2311001T3 (en) | USE IN FASTES OF PHARMACEUTICAL COMPOSITIONS THAT INCLUDE OXCARBAZEPINA. | |
WO2004054574A1 (en) | Solid drug for oral use | |
CN106074589A (en) | Comprise the compositions of S S-adenosylmethionine and epicatechol gallate | |
HU228149B1 (en) | Film coated tablet of paracetamol and domperidone | |
CN110507620B (en) | Compound glucosamine sulfate dispersible tablet and preparation method thereof | |
JP2023544327A (en) | Pharmaceutical formulations for treating diseases mediated by KDM1A | |
US11612566B2 (en) | Lamotrigine oral liquid suspension and use thereof | |
KR101320016B1 (en) | Combination containing stabilized coenzyme q10, multivitamins and minerals | |
CN112336722A (en) | Norfloxacin composition and preparation method thereof | |
WO2004002486A2 (en) | Ciprofloxacin hci | |
US11224591B2 (en) | Pharmaceutical compositions comprising rifaximin | |
CN101675932B (en) | Composition for preventing and treating amyotrophic lateral sclerosis | |
US20240000737A1 (en) | Substances for treatment of hyperuricaemia | |
EP4349334A1 (en) | Palatable liquid solution containing high concentration of miglustat | |
Ogwal et al. | Biovailability and stability of erythromycin delayed release tablets | |
Madhu | Formulation Development and Invitro Evaluation of Sustained Release Oral Dosage Forms Containing Cefixime | |
EP1715894A2 (en) | Stable gabapentin compositions | |
CN106880603A (en) | A kind of oral disnitegration tablet containing Topiroxostat and preparation method thereof | |
Bagbi et al. | Product quality assessment of brands of cefuroxime axetil tablets marketed in southern and western Nigeria | |
Jayaselvi | Formulation and Evaluation of Floating Tablet formulation and Evaluation of Floating Tablets of Ciprofloxacin HCL. | |
Dimitrov et al. | Extemporaneous preparation of paediatric oral formulations with sildenafil citrate | |
CA2212980A1 (en) | Glucomannan-containing orally administered pharmaceutical preparations with sustained effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10519467 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003761874 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038202077 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003761874 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |